Relationship between metabolism and biomass of medically important zygomycetes
Open Access
- 1 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 44 (5) , 429-438
- https://doi.org/10.1080/13693780600644878
Abstract
Little is known about the relationships between metabolic activity and fungal biomass or time of incubation for medically important fungal pathogens. Understanding these relationships may be especially relevant for rapidly growing organisms, such as zygomycetes. A range of inocula of five clinical isolates of zygomycetes (one each of Rhizopus oryzae,Rhizopus microsporus, Cunninghamella bertholletiae, Mucor circinelloides and Absidia corymbifera) were incubated for 6, 8, 12, 24 and 48 h, after which hyphal mass was assessed spectrophotometrically and metabolic activity was measured using various concentrations of XTT and menadione. Both linear regression and the Boltzmann sigmoid model were used and compared for description of relationships between metabolic activity, biomass and time of incubation. Modeling was further applied to eleven additional zygomycete isolates. The relationships of biomass or metabolic activity as a function of time of incubation were well described with the Boltzmann sigmoid model. The latter was superior to linear regression in describing the relationship between metabolic activity and fungal biomass. For all isolates of zygomycetes, increases in metabolic activity preceded increases in biomass. Inter-species differences in growth patterns were observed, with Rhizopus microsporus and Mucor spp. reaching the plateau of growth earlier compared to other species. These findings on the temporal relationship and inter-species differences of hyphal growth and metabolic activity for zygomycetes may be useful in the design and interpretation of in vitro studies of these emerging pathogens.Keywords
This publication has 16 references indexed in Scilit:
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Zygomycosis in a Tertiary‐Care Cancer Center in the Era ofAspergillus‐Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent CasesThe Journal of Infectious Diseases, 2005
- In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole againstAspergillus,Fusarium, andScedosporiumsppAntimicrobial Agents and Chemotherapy, 2005
- In Vitro Activity of Caspofungin Combined with Sulfamethoxazole against Clinical Isolates of Aspergillus sppAntimicrobial Agents and Chemotherapy, 2004
- Pentamidine Is Active In Vitro againstFusariumSpeciesAntimicrobial Agents and Chemotherapy, 2003
- Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of Aspergillus SpeciesJournal of Clinical Microbiology, 2001
- Utility of 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2 H -Tetrazolium Hydroxide (XTT) and Minimum Effective Concentration Assays in the Determination of Antifungal Susceptibility of Aspergillus fumigatus to the Lipopeptide Class of CompoundsJournal of Clinical Microbiology, 2001
- Zygomycetes in Human DiseaseClinical Microbiology Reviews, 2000
- Comparison of a 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2 H -Tetrazolium Hydroxide (XTT) Colorimetric Method with the Standardized National Committee for Clinical Laboratory Standards Method of Testing Clinical Yeast Isolates for Susceptibility to Antifungal AgentsJournal of Clinical Microbiology, 1998
- A Simplified New Assay for Assessment of Fungal Cell Damage with the Tetrazolium Dye, (2,3)-bis-(2-Methoxy-4-Nitro-5-Sulphenyl)-(2H)-Tetrazolium-5-Carboxanilide (XTT)The Journal of Infectious Diseases, 1995